Table 3.
Univariate and multivariable hierarchical linear regression models predicting change in SDMT score at week 12 in patients treated with dalfampridine (n = 71).
| β | 95% confidence intervals | p-value | Adjusted R2 | ||
|---|---|---|---|---|---|
| Lower bound | Upper bound | ||||
| Univariate analysis | |||||
| Sex (male versus female) | 1.45 | −1.43 | 4.34 | 0.32 | |
| Age (each year) | 0.02 | −0.17 | 0.20 | 0.86 | |
| Formal education (⩽13 versus >13 years) | 0.32 | −3.11 | 3.76 | 0.85 | |
| Disease duration (each year) | −0.07 | −0.23 | 0.10 | 0.43 | |
| Phenotype (SP/PP versus RR) | 0.99 | −3.54 | 5.52 | 0.66 | |
| EDSS score (each step) | −0.98 | −1.94 | −0.02 | 0.047 | |
| DMT exposure (yes versus no) | −0.63 | −3.60 | 2.35 | 0.68 | |
| T25-FWT (each second) | −0.58 | −1.14 | −0.01 | 0.047 | |
| 9HPT dominant hand (each second) | −0.16 | −0.28 | −0.04 | 0.011 | |
| 9HPT non-dominant hand (each second) | −0.15 | −0.29 | −0.01 | 0.044 | |
| SDMT (each point) | −0.07 | −0.26 | 0.12 | 0.47 | |
| PASAT (each point) | 0.11 | 0.01 | 0.22 | 0.048 | |
| Multivariable hierarchical analysis | |||||
| Step 1 | |||||
| No predictors | |||||
| Step 2 | 0.05 | ||||
| Constant | 13.61 | 9.86 | 17.36 | <0.001 | |
| EDSS score (each step) | −1.11 | −2.12 | −0.10 | 0.033 | |
| Step 3 | 0.24 | ||||
| Constant | 22.44 | 14.50 | 30.39 | <0.001 | |
| 9HPT dominant hand (each second) | −0.30 | −0.48 | −0.12 | 0.001 | |
| SDMT (each point) | −0.27 | −0.47 | −0.07 | 0.01 | |
| PASAT (each point) | 0.13 | 0.01 | 0.26 | 0.032 | |
9HPT, 9-Hole Peg Test; DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; PASAT, Paced Auditory Serial Addition Test; PP, primary progressive; RR, relapsing–remitting; SDMT, Symbol Digit Modalities Test; SP, secondary progressive; T25-FWT, Timed 25-Foot Walk Test.